nodes	percent_of_prediction	percent_of_DWPC	metapath
Fondaparinux sodium—Dermatitis—Mechlorethamine—lymphatic system cancer	0.00243	0.00243	CcSEcCtD
Fondaparinux sodium—Hyperhidrosis—Fludarabine—lymphatic system cancer	0.00242	0.00242	CcSEcCtD
Fondaparinux sodium—Flushing—Bleomycin—lymphatic system cancer	0.00239	0.00239	CcSEcCtD
Fondaparinux sodium—Anorexia—Fludarabine—lymphatic system cancer	0.00238	0.00238	CcSEcCtD
Fondaparinux sodium—Extravasation—Methotrexate—lymphatic system cancer	0.00238	0.00238	CcSEcCtD
Fondaparinux sodium—Acute coronary syndrome—Vincristine—lymphatic system cancer	0.00236	0.00236	CcSEcCtD
Fondaparinux sodium—Myocardial infarction—Vincristine—lymphatic system cancer	0.00235	0.00235	CcSEcCtD
Fondaparinux sodium—Feeling abnormal—Teniposide—lymphatic system cancer	0.00234	0.00234	CcSEcCtD
Fondaparinux sodium—Gastrointestinal pain—Teniposide—lymphatic system cancer	0.00233	0.00233	CcSEcCtD
Fondaparinux sodium—Acute coronary syndrome—Mitoxantrone—lymphatic system cancer	0.0023	0.0023	CcSEcCtD
Fondaparinux sodium—Renal failure—Mitoxantrone—lymphatic system cancer	0.00229	0.00229	CcSEcCtD
Fondaparinux sodium—Nausea—Mechlorethamine—lymphatic system cancer	0.00229	0.00229	CcSEcCtD
Fondaparinux sodium—Myocardial infarction—Mitoxantrone—lymphatic system cancer	0.00229	0.00229	CcSEcCtD
Fondaparinux sodium—Hyperbilirubinaemia—Methotrexate—lymphatic system cancer	0.00228	0.00228	CcSEcCtD
Fondaparinux sodium—Urinary tract infection—Mitoxantrone—lymphatic system cancer	0.00227	0.00227	CcSEcCtD
Fondaparinux sodium—Haemoglobin—Carmustine—lymphatic system cancer	0.00226	0.00226	CcSEcCtD
Fondaparinux sodium—Urticaria—Teniposide—lymphatic system cancer	0.00226	0.00226	CcSEcCtD
Fondaparinux sodium—Oliguria—Methotrexate—lymphatic system cancer	0.00225	0.00225	CcSEcCtD
Fondaparinux sodium—Haemorrhage—Carmustine—lymphatic system cancer	0.00225	0.00225	CcSEcCtD
Fondaparinux sodium—Body temperature increased—Teniposide—lymphatic system cancer	0.00225	0.00225	CcSEcCtD
Fondaparinux sodium—Abdominal pain—Teniposide—lymphatic system cancer	0.00225	0.00225	CcSEcCtD
Fondaparinux sodium—Paraesthesia—Fludarabine—lymphatic system cancer	0.00224	0.00224	CcSEcCtD
Fondaparinux sodium—Hypoaesthesia—Carmustine—lymphatic system cancer	0.00224	0.00224	CcSEcCtD
Fondaparinux sodium—Dyspnoea—Fludarabine—lymphatic system cancer	0.00223	0.00223	CcSEcCtD
Fondaparinux sodium—Haematuria—Mitoxantrone—lymphatic system cancer	0.00222	0.00222	CcSEcCtD
Fondaparinux sodium—Oedema peripheral—Carmustine—lymphatic system cancer	0.00222	0.00222	CcSEcCtD
Fondaparinux sodium—Dyspepsia—Fludarabine—lymphatic system cancer	0.0022	0.0022	CcSEcCtD
Fondaparinux sodium—Ulcer—Methotrexate—lymphatic system cancer	0.0022	0.0022	CcSEcCtD
Fondaparinux sodium—Hepatic enzyme increased—Methotrexate—lymphatic system cancer	0.0022	0.0022	CcSEcCtD
Fondaparinux sodium—Decreased appetite—Fludarabine—lymphatic system cancer	0.00217	0.00217	CcSEcCtD
Fondaparinux sodium—Gastrointestinal disorder—Fludarabine—lymphatic system cancer	0.00216	0.00216	CcSEcCtD
Fondaparinux sodium—Fatigue—Fludarabine—lymphatic system cancer	0.00215	0.00215	CcSEcCtD
Fondaparinux sodium—Hypoaesthesia—Vincristine—lymphatic system cancer	0.00214	0.00214	CcSEcCtD
Fondaparinux sodium—Pain—Fludarabine—lymphatic system cancer	0.00214	0.00214	CcSEcCtD
Fondaparinux sodium—Constipation—Fludarabine—lymphatic system cancer	0.00214	0.00214	CcSEcCtD
Fondaparinux sodium—Haemoglobin—Mitoxantrone—lymphatic system cancer	0.0021	0.0021	CcSEcCtD
Fondaparinux sodium—Hypersensitivity—Teniposide—lymphatic system cancer	0.0021	0.0021	CcSEcCtD
Fondaparinux sodium—Haemorrhage—Mitoxantrone—lymphatic system cancer	0.00209	0.00209	CcSEcCtD
Fondaparinux sodium—Flushing—Carmustine—lymphatic system cancer	0.00209	0.00209	CcSEcCtD
Fondaparinux sodium—Anaemia—Bleomycin—lymphatic system cancer	0.00208	0.00208	CcSEcCtD
Fondaparinux sodium—Feeling abnormal—Fludarabine—lymphatic system cancer	0.00206	0.00206	CcSEcCtD
Fondaparinux sodium—Asthenia—Teniposide—lymphatic system cancer	0.00204	0.00204	CcSEcCtD
Fondaparinux sodium—Pruritus—Teniposide—lymphatic system cancer	0.00201	0.00201	CcSEcCtD
Fondaparinux sodium—Arrhythmia—Carmustine—lymphatic system cancer	0.00201	0.00201	CcSEcCtD
Fondaparinux sodium—Body temperature increased—Fludarabine—lymphatic system cancer	0.00198	0.00198	CcSEcCtD
Fondaparinux sodium—Malnutrition—Carmustine—lymphatic system cancer	0.00196	0.00196	CcSEcCtD
Fondaparinux sodium—Cough—Bleomycin—lymphatic system cancer	0.00196	0.00196	CcSEcCtD
Fondaparinux sodium—Angiopathy—Vincristine—lymphatic system cancer	0.00195	0.00195	CcSEcCtD
Fondaparinux sodium—Diarrhoea—Teniposide—lymphatic system cancer	0.00195	0.00195	CcSEcCtD
Fondaparinux sodium—Mediastinal disorder—Vincristine—lymphatic system cancer	0.00194	0.00194	CcSEcCtD
Fondaparinux sodium—Chest pain—Bleomycin—lymphatic system cancer	0.00191	0.00191	CcSEcCtD
Fondaparinux sodium—Back pain—Carmustine—lymphatic system cancer	0.0019	0.0019	CcSEcCtD
Fondaparinux sodium—Arrhythmia—Mitoxantrone—lymphatic system cancer	0.00187	0.00187	CcSEcCtD
Fondaparinux sodium—Confusional state—Bleomycin—lymphatic system cancer	0.00185	0.00185	CcSEcCtD
Fondaparinux sodium—Vision blurred—Carmustine—lymphatic system cancer	0.00185	0.00185	CcSEcCtD
Fondaparinux sodium—Hypersensitivity—Fludarabine—lymphatic system cancer	0.00184	0.00184	CcSEcCtD
Fondaparinux sodium—Anaphylactic shock—Bleomycin—lymphatic system cancer	0.00183	0.00183	CcSEcCtD
Fondaparinux sodium—Oedema—Bleomycin—lymphatic system cancer	0.00183	0.00183	CcSEcCtD
Fondaparinux sodium—Infection—Bleomycin—lymphatic system cancer	0.00182	0.00182	CcSEcCtD
Fondaparinux sodium—Anaemia—Carmustine—lymphatic system cancer	0.00181	0.00181	CcSEcCtD
Fondaparinux sodium—Back pain—Vincristine—lymphatic system cancer	0.00181	0.00181	CcSEcCtD
Fondaparinux sodium—Vomiting—Teniposide—lymphatic system cancer	0.00181	0.00181	CcSEcCtD
Fondaparinux sodium—Sepsis—Methotrexate—lymphatic system cancer	0.0018	0.0018	CcSEcCtD
Fondaparinux sodium—Thrombocytopenia—Bleomycin—lymphatic system cancer	0.00179	0.00179	CcSEcCtD
Fondaparinux sodium—Asthenia—Fludarabine—lymphatic system cancer	0.00179	0.00179	CcSEcCtD
Fondaparinux sodium—Rash—Teniposide—lymphatic system cancer	0.00179	0.00179	CcSEcCtD
Fondaparinux sodium—Dermatitis—Teniposide—lymphatic system cancer	0.00179	0.00179	CcSEcCtD
Fondaparinux sodium—Dysgeusia—Mitoxantrone—lymphatic system cancer	0.00178	0.00178	CcSEcCtD
Fondaparinux sodium—Headache—Teniposide—lymphatic system cancer	0.00178	0.00178	CcSEcCtD
Fondaparinux sodium—Pruritus—Fludarabine—lymphatic system cancer	0.00177	0.00177	CcSEcCtD
Fondaparinux sodium—Back pain—Mitoxantrone—lymphatic system cancer	0.00176	0.00176	CcSEcCtD
Fondaparinux sodium—Anorexia—Bleomycin—lymphatic system cancer	0.00175	0.00175	CcSEcCtD
Fondaparinux sodium—Anaemia—Vincristine—lymphatic system cancer	0.00173	0.00173	CcSEcCtD
Fondaparinux sodium—Vision blurred—Mitoxantrone—lymphatic system cancer	0.00172	0.00172	CcSEcCtD
Fondaparinux sodium—Hypotension—Bleomycin—lymphatic system cancer	0.00171	0.00171	CcSEcCtD
Fondaparinux sodium—Diarrhoea—Fludarabine—lymphatic system cancer	0.00171	0.00171	CcSEcCtD
Fondaparinux sodium—Convulsion—Carmustine—lymphatic system cancer	0.0017	0.0017	CcSEcCtD
Fondaparinux sodium—Nausea—Teniposide—lymphatic system cancer	0.00169	0.00169	CcSEcCtD
Fondaparinux sodium—Anaemia—Mitoxantrone—lymphatic system cancer	0.00168	0.00168	CcSEcCtD
Fondaparinux sodium—Vertigo—Vincristine—lymphatic system cancer	0.00168	0.00168	CcSEcCtD
Fondaparinux sodium—Chest pain—Carmustine—lymphatic system cancer	0.00167	0.00167	CcSEcCtD
Fondaparinux sodium—Anxiety—Carmustine—lymphatic system cancer	0.00166	0.00166	CcSEcCtD
Fondaparinux sodium—Paraesthesia—Bleomycin—lymphatic system cancer	0.00165	0.00165	CcSEcCtD
Fondaparinux sodium—Dyspnoea—Bleomycin—lymphatic system cancer	0.00163	0.00163	CcSEcCtD
Fondaparinux sodium—Renal failure acute—Methotrexate—lymphatic system cancer	0.00163	0.00163	CcSEcCtD
Fondaparinux sodium—Convulsion—Vincristine—lymphatic system cancer	0.00162	0.00162	CcSEcCtD
Fondaparinux sodium—Confusional state—Carmustine—lymphatic system cancer	0.00161	0.00161	CcSEcCtD
Fondaparinux sodium—Oedema—Carmustine—lymphatic system cancer	0.0016	0.0016	CcSEcCtD
Fondaparinux sodium—Decreased appetite—Bleomycin—lymphatic system cancer	0.00159	0.00159	CcSEcCtD
Fondaparinux sodium—Cough—Mitoxantrone—lymphatic system cancer	0.00159	0.00159	CcSEcCtD
Fondaparinux sodium—Infection—Carmustine—lymphatic system cancer	0.00159	0.00159	CcSEcCtD
Fondaparinux sodium—Vomiting—Fludarabine—lymphatic system cancer	0.00159	0.00159	CcSEcCtD
Fondaparinux sodium—Convulsion—Mitoxantrone—lymphatic system cancer	0.00158	0.00158	CcSEcCtD
Fondaparinux sodium—Rash—Fludarabine—lymphatic system cancer	0.00158	0.00158	CcSEcCtD
Fondaparinux sodium—Dermatitis—Fludarabine—lymphatic system cancer	0.00157	0.00157	CcSEcCtD
Fondaparinux sodium—Pain—Bleomycin—lymphatic system cancer	0.00157	0.00157	CcSEcCtD
Fondaparinux sodium—Thrombocytopenia—Carmustine—lymphatic system cancer	0.00157	0.00157	CcSEcCtD
Fondaparinux sodium—Headache—Fludarabine—lymphatic system cancer	0.00157	0.00157	CcSEcCtD
Fondaparinux sodium—Tachycardia—Carmustine—lymphatic system cancer	0.00156	0.00156	CcSEcCtD
Fondaparinux sodium—Chest pain—Mitoxantrone—lymphatic system cancer	0.00155	0.00155	CcSEcCtD
Fondaparinux sodium—Anxiety—Mitoxantrone—lymphatic system cancer	0.00155	0.00155	CcSEcCtD
Fondaparinux sodium—Cerebrovascular accident—Methotrexate—lymphatic system cancer	0.00154	0.00154	CcSEcCtD
Fondaparinux sodium—Oedema—Vincristine—lymphatic system cancer	0.00153	0.00153	CcSEcCtD
Fondaparinux sodium—Anaphylactic shock—Vincristine—lymphatic system cancer	0.00153	0.00153	CcSEcCtD
Fondaparinux sodium—Anorexia—Carmustine—lymphatic system cancer	0.00152	0.00152	CcSEcCtD
Fondaparinux sodium—Infection—Vincristine—lymphatic system cancer	0.00152	0.00152	CcSEcCtD
Fondaparinux sodium—Feeling abnormal—Bleomycin—lymphatic system cancer	0.00151	0.00151	CcSEcCtD
Fondaparinux sodium—Confusional state—Mitoxantrone—lymphatic system cancer	0.0015	0.0015	CcSEcCtD
Fondaparinux sodium—Nervous system disorder—Vincristine—lymphatic system cancer	0.0015	0.0015	CcSEcCtD
Fondaparinux sodium—Thrombocytopenia—Vincristine—lymphatic system cancer	0.00149	0.00149	CcSEcCtD
Fondaparinux sodium—Hypotension—Carmustine—lymphatic system cancer	0.00149	0.00149	CcSEcCtD
Fondaparinux sodium—Anaphylactic shock—Mitoxantrone—lymphatic system cancer	0.00149	0.00149	CcSEcCtD
Fondaparinux sodium—Oedema—Mitoxantrone—lymphatic system cancer	0.00149	0.00149	CcSEcCtD
Fondaparinux sodium—Nausea—Fludarabine—lymphatic system cancer	0.00148	0.00148	CcSEcCtD
Fondaparinux sodium—Infection—Mitoxantrone—lymphatic system cancer	0.00148	0.00148	CcSEcCtD
Fondaparinux sodium—Hyperhidrosis—Vincristine—lymphatic system cancer	0.00148	0.00148	CcSEcCtD
Fondaparinux sodium—Shock—Mitoxantrone—lymphatic system cancer	0.00146	0.00146	CcSEcCtD
Fondaparinux sodium—Thrombocytopenia—Mitoxantrone—lymphatic system cancer	0.00146	0.00146	CcSEcCtD
Fondaparinux sodium—Urticaria—Bleomycin—lymphatic system cancer	0.00146	0.00146	CcSEcCtD
Fondaparinux sodium—Anorexia—Vincristine—lymphatic system cancer	0.00146	0.00146	CcSEcCtD
Fondaparinux sodium—Tachycardia—Mitoxantrone—lymphatic system cancer	0.00145	0.00145	CcSEcCtD
Fondaparinux sodium—Body temperature increased—Bleomycin—lymphatic system cancer	0.00145	0.00145	CcSEcCtD
Fondaparinux sodium—Insomnia—Carmustine—lymphatic system cancer	0.00145	0.00145	CcSEcCtD
Fondaparinux sodium—Skin disorder—Mitoxantrone—lymphatic system cancer	0.00144	0.00144	CcSEcCtD
Fondaparinux sodium—Irritability—Methotrexate—lymphatic system cancer	0.00144	0.00144	CcSEcCtD
Fondaparinux sodium—Hyperhidrosis—Mitoxantrone—lymphatic system cancer	0.00144	0.00144	CcSEcCtD
Fondaparinux sodium—Paraesthesia—Carmustine—lymphatic system cancer	0.00144	0.00144	CcSEcCtD
Fondaparinux sodium—Hypotension—Vincristine—lymphatic system cancer	0.00143	0.00143	CcSEcCtD
Fondaparinux sodium—Dyspnoea—Carmustine—lymphatic system cancer	0.00143	0.00143	CcSEcCtD
Fondaparinux sodium—Somnolence—Carmustine—lymphatic system cancer	0.00142	0.00142	CcSEcCtD
Fondaparinux sodium—Anorexia—Mitoxantrone—lymphatic system cancer	0.00142	0.00142	CcSEcCtD
Fondaparinux sodium—Decreased appetite—Carmustine—lymphatic system cancer	0.00139	0.00139	CcSEcCtD
Fondaparinux sodium—Hypotension—Mitoxantrone—lymphatic system cancer	0.00139	0.00139	CcSEcCtD
Fondaparinux sodium—Insomnia—Vincristine—lymphatic system cancer	0.00138	0.00138	CcSEcCtD
Fondaparinux sodium—Gastrointestinal disorder—Carmustine—lymphatic system cancer	0.00138	0.00138	CcSEcCtD
Fondaparinux sodium—Paraesthesia—Vincristine—lymphatic system cancer	0.00137	0.00137	CcSEcCtD
Fondaparinux sodium—Pain—Carmustine—lymphatic system cancer	0.00137	0.00137	CcSEcCtD
Fondaparinux sodium—Constipation—Carmustine—lymphatic system cancer	0.00137	0.00137	CcSEcCtD
Fondaparinux sodium—Hypersensitivity—Bleomycin—lymphatic system cancer	0.00135	0.00135	CcSEcCtD
Fondaparinux sodium—Paraesthesia—Mitoxantrone—lymphatic system cancer	0.00134	0.00134	CcSEcCtD
Fondaparinux sodium—Decreased appetite—Vincristine—lymphatic system cancer	0.00133	0.00133	CcSEcCtD
Fondaparinux sodium—Dyspnoea—Mitoxantrone—lymphatic system cancer	0.00133	0.00133	CcSEcCtD
Fondaparinux sodium—Somnolence—Mitoxantrone—lymphatic system cancer	0.00132	0.00132	CcSEcCtD
Fondaparinux sodium—Gastrointestinal disorder—Vincristine—lymphatic system cancer	0.00132	0.00132	CcSEcCtD
Fondaparinux sodium—Feeling abnormal—Carmustine—lymphatic system cancer	0.00132	0.00132	CcSEcCtD
Fondaparinux sodium—Fatigue—Vincristine—lymphatic system cancer	0.00132	0.00132	CcSEcCtD
Fondaparinux sodium—Asthenia—Bleomycin—lymphatic system cancer	0.00131	0.00131	CcSEcCtD
Fondaparinux sodium—Dyspepsia—Mitoxantrone—lymphatic system cancer	0.00131	0.00131	CcSEcCtD
Fondaparinux sodium—Gastrointestinal pain—Carmustine—lymphatic system cancer	0.00131	0.00131	CcSEcCtD
Fondaparinux sodium—Constipation—Vincristine—lymphatic system cancer	0.00131	0.00131	CcSEcCtD
Fondaparinux sodium—Pain—Vincristine—lymphatic system cancer	0.00131	0.00131	CcSEcCtD
Fondaparinux sodium—Pruritus—Bleomycin—lymphatic system cancer	0.0013	0.0013	CcSEcCtD
Fondaparinux sodium—Decreased appetite—Mitoxantrone—lymphatic system cancer	0.00129	0.00129	CcSEcCtD
Fondaparinux sodium—Fatigue—Mitoxantrone—lymphatic system cancer	0.00128	0.00128	CcSEcCtD
Fondaparinux sodium—Constipation—Mitoxantrone—lymphatic system cancer	0.00127	0.00127	CcSEcCtD
Fondaparinux sodium—Pain—Mitoxantrone—lymphatic system cancer	0.00127	0.00127	CcSEcCtD
Fondaparinux sodium—Abdominal pain—Carmustine—lymphatic system cancer	0.00126	0.00126	CcSEcCtD
Fondaparinux sodium—Body temperature increased—Carmustine—lymphatic system cancer	0.00126	0.00126	CcSEcCtD
Fondaparinux sodium—Gastrointestinal pain—Vincristine—lymphatic system cancer	0.00125	0.00125	CcSEcCtD
Fondaparinux sodium—Feeling abnormal—Mitoxantrone—lymphatic system cancer	0.00123	0.00123	CcSEcCtD
Fondaparinux sodium—Gastrointestinal pain—Mitoxantrone—lymphatic system cancer	0.00122	0.00122	CcSEcCtD
Fondaparinux sodium—Abdominal pain—Vincristine—lymphatic system cancer	0.00121	0.00121	CcSEcCtD
Fondaparinux sodium—Body temperature increased—Vincristine—lymphatic system cancer	0.00121	0.00121	CcSEcCtD
Fondaparinux sodium—Urticaria—Mitoxantrone—lymphatic system cancer	0.00118	0.00118	CcSEcCtD
Fondaparinux sodium—Hypersensitivity—Carmustine—lymphatic system cancer	0.00118	0.00118	CcSEcCtD
Fondaparinux sodium—Abdominal pain—Mitoxantrone—lymphatic system cancer	0.00118	0.00118	CcSEcCtD
Fondaparinux sodium—Body temperature increased—Mitoxantrone—lymphatic system cancer	0.00118	0.00118	CcSEcCtD
Fondaparinux sodium—Vomiting—Bleomycin—lymphatic system cancer	0.00117	0.00117	CcSEcCtD
Fondaparinux sodium—Infestation—Methotrexate—lymphatic system cancer	0.00116	0.00116	CcSEcCtD
Fondaparinux sodium—Infestation NOS—Methotrexate—lymphatic system cancer	0.00116	0.00116	CcSEcCtD
Fondaparinux sodium—Rash—Bleomycin—lymphatic system cancer	0.00116	0.00116	CcSEcCtD
Fondaparinux sodium—Dermatitis—Bleomycin—lymphatic system cancer	0.00115	0.00115	CcSEcCtD
Fondaparinux sodium—Asthenia—Carmustine—lymphatic system cancer	0.00115	0.00115	CcSEcCtD
Fondaparinux sodium—Renal failure—Methotrexate—lymphatic system cancer	0.00114	0.00114	CcSEcCtD
Fondaparinux sodium—Hypersensitivity—Vincristine—lymphatic system cancer	0.00112	0.00112	CcSEcCtD
Fondaparinux sodium—Haematuria—Methotrexate—lymphatic system cancer	0.00111	0.00111	CcSEcCtD
Fondaparinux sodium—Hepatobiliary disease—Methotrexate—lymphatic system cancer	0.0011	0.0011	CcSEcCtD
Fondaparinux sodium—Epistaxis—Methotrexate—lymphatic system cancer	0.0011	0.0011	CcSEcCtD
Fondaparinux sodium—Hypersensitivity—Mitoxantrone—lymphatic system cancer	0.0011	0.0011	CcSEcCtD
Fondaparinux sodium—Asthenia—Vincristine—lymphatic system cancer	0.0011	0.0011	CcSEcCtD
Fondaparinux sodium—Diarrhoea—Carmustine—lymphatic system cancer	0.00109	0.00109	CcSEcCtD
Fondaparinux sodium—Nausea—Bleomycin—lymphatic system cancer	0.00109	0.00109	CcSEcCtD
Fondaparinux sodium—Asthenia—Mitoxantrone—lymphatic system cancer	0.00107	0.00107	CcSEcCtD
Fondaparinux sodium—Dizziness—Carmustine—lymphatic system cancer	0.00106	0.00106	CcSEcCtD
Fondaparinux sodium—Haemoglobin—Methotrexate—lymphatic system cancer	0.00105	0.00105	CcSEcCtD
Fondaparinux sodium—Diarrhoea—Vincristine—lymphatic system cancer	0.00104	0.00104	CcSEcCtD
Fondaparinux sodium—Haemorrhage—Methotrexate—lymphatic system cancer	0.00104	0.00104	CcSEcCtD
Fondaparinux sodium—Diarrhoea—Mitoxantrone—lymphatic system cancer	0.00102	0.00102	CcSEcCtD
Fondaparinux sodium—Vomiting—Carmustine—lymphatic system cancer	0.00102	0.00102	CcSEcCtD
Fondaparinux sodium—Dizziness—Vincristine—lymphatic system cancer	0.00101	0.00101	CcSEcCtD
Fondaparinux sodium—Rash—Carmustine—lymphatic system cancer	0.00101	0.00101	CcSEcCtD
Fondaparinux sodium—Dermatitis—Carmustine—lymphatic system cancer	0.00101	0.00101	CcSEcCtD
Fondaparinux sodium—Headache—Carmustine—lymphatic system cancer	0.001	0.001	CcSEcCtD
Fondaparinux sodium—Vomiting—Vincristine—lymphatic system cancer	0.000971	0.000971	CcSEcCtD
Fondaparinux sodium—Rash—Vincristine—lymphatic system cancer	0.000963	0.000963	CcSEcCtD
Fondaparinux sodium—Dermatitis—Vincristine—lymphatic system cancer	0.000962	0.000962	CcSEcCtD
Fondaparinux sodium—Headache—Vincristine—lymphatic system cancer	0.000957	0.000957	CcSEcCtD
Fondaparinux sodium—Nausea—Carmustine—lymphatic system cancer	0.00095	0.00095	CcSEcCtD
Fondaparinux sodium—Angiopathy—Methotrexate—lymphatic system cancer	0.000946	0.000946	CcSEcCtD
Fondaparinux sodium—Vomiting—Mitoxantrone—lymphatic system cancer	0.000945	0.000945	CcSEcCtD
Fondaparinux sodium—Immune system disorder—Methotrexate—lymphatic system cancer	0.000942	0.000942	CcSEcCtD
Fondaparinux sodium—Mediastinal disorder—Methotrexate—lymphatic system cancer	0.00094	0.00094	CcSEcCtD
Fondaparinux sodium—Rash—Mitoxantrone—lymphatic system cancer	0.000938	0.000938	CcSEcCtD
Fondaparinux sodium—Dermatitis—Mitoxantrone—lymphatic system cancer	0.000937	0.000937	CcSEcCtD
Fondaparinux sodium—Headache—Mitoxantrone—lymphatic system cancer	0.000932	0.000932	CcSEcCtD
Fondaparinux sodium—Malnutrition—Methotrexate—lymphatic system cancer	0.000908	0.000908	CcSEcCtD
Fondaparinux sodium—Nausea—Vincristine—lymphatic system cancer	0.000907	0.000907	CcSEcCtD
Fondaparinux sodium—Dysgeusia—Methotrexate—lymphatic system cancer	0.000889	0.000889	CcSEcCtD
Fondaparinux sodium—Nausea—Mitoxantrone—lymphatic system cancer	0.000883	0.000883	CcSEcCtD
Fondaparinux sodium—Back pain—Methotrexate—lymphatic system cancer	0.000878	0.000878	CcSEcCtD
Fondaparinux sodium—Vision blurred—Methotrexate—lymphatic system cancer	0.000856	0.000856	CcSEcCtD
Fondaparinux sodium—Anaemia—Methotrexate—lymphatic system cancer	0.000839	0.000839	CcSEcCtD
Fondaparinux sodium—Vertigo—Methotrexate—lymphatic system cancer	0.000816	0.000816	CcSEcCtD
Fondaparinux sodium—Cough—Methotrexate—lymphatic system cancer	0.000792	0.000792	CcSEcCtD
Fondaparinux sodium—Convulsion—Methotrexate—lymphatic system cancer	0.000787	0.000787	CcSEcCtD
Fondaparinux sodium—Chest pain—Methotrexate—lymphatic system cancer	0.000773	0.000773	CcSEcCtD
Fondaparinux sodium—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—lymphatic system cancer	0.000768	0.000768	CcSEcCtD
Fondaparinux sodium—Confusional state—Methotrexate—lymphatic system cancer	0.000747	0.000747	CcSEcCtD
Fondaparinux sodium—Anaphylactic shock—Methotrexate—lymphatic system cancer	0.000741	0.000741	CcSEcCtD
Fondaparinux sodium—Infection—Methotrexate—lymphatic system cancer	0.000736	0.000736	CcSEcCtD
Fondaparinux sodium—Nervous system disorder—Methotrexate—lymphatic system cancer	0.000727	0.000727	CcSEcCtD
Fondaparinux sodium—Thrombocytopenia—Methotrexate—lymphatic system cancer	0.000725	0.000725	CcSEcCtD
Fondaparinux sodium—Skin disorder—Methotrexate—lymphatic system cancer	0.00072	0.00072	CcSEcCtD
Fondaparinux sodium—Hyperhidrosis—Methotrexate—lymphatic system cancer	0.000716	0.000716	CcSEcCtD
Fondaparinux sodium—Anorexia—Methotrexate—lymphatic system cancer	0.000706	0.000706	CcSEcCtD
Fondaparinux sodium—Hypotension—Methotrexate—lymphatic system cancer	0.000692	0.000692	CcSEcCtD
Fondaparinux sodium—Insomnia—Methotrexate—lymphatic system cancer	0.00067	0.00067	CcSEcCtD
Fondaparinux sodium—Paraesthesia—Methotrexate—lymphatic system cancer	0.000665	0.000665	CcSEcCtD
Fondaparinux sodium—Dyspnoea—Methotrexate—lymphatic system cancer	0.000661	0.000661	CcSEcCtD
Fondaparinux sodium—Somnolence—Methotrexate—lymphatic system cancer	0.000659	0.000659	CcSEcCtD
Fondaparinux sodium—Dyspepsia—Methotrexate—lymphatic system cancer	0.000652	0.000652	CcSEcCtD
Fondaparinux sodium—Decreased appetite—Methotrexate—lymphatic system cancer	0.000644	0.000644	CcSEcCtD
Fondaparinux sodium—Gastrointestinal disorder—Methotrexate—lymphatic system cancer	0.00064	0.00064	CcSEcCtD
Fondaparinux sodium—Fatigue—Methotrexate—lymphatic system cancer	0.000639	0.000639	CcSEcCtD
Fondaparinux sodium—Pain—Methotrexate—lymphatic system cancer	0.000634	0.000634	CcSEcCtD
Fondaparinux sodium—Feeling abnormal—Methotrexate—lymphatic system cancer	0.000611	0.000611	CcSEcCtD
Fondaparinux sodium—Gastrointestinal pain—Methotrexate—lymphatic system cancer	0.000606	0.000606	CcSEcCtD
Fondaparinux sodium—Urticaria—Methotrexate—lymphatic system cancer	0.000589	0.000589	CcSEcCtD
Fondaparinux sodium—Abdominal pain—Methotrexate—lymphatic system cancer	0.000586	0.000586	CcSEcCtD
Fondaparinux sodium—Body temperature increased—Methotrexate—lymphatic system cancer	0.000586	0.000586	CcSEcCtD
Fondaparinux sodium—Hypersensitivity—Methotrexate—lymphatic system cancer	0.000546	0.000546	CcSEcCtD
Fondaparinux sodium—Asthenia—Methotrexate—lymphatic system cancer	0.000532	0.000532	CcSEcCtD
Fondaparinux sodium—Pruritus—Methotrexate—lymphatic system cancer	0.000524	0.000524	CcSEcCtD
Fondaparinux sodium—Diarrhoea—Methotrexate—lymphatic system cancer	0.000507	0.000507	CcSEcCtD
Fondaparinux sodium—Dizziness—Methotrexate—lymphatic system cancer	0.00049	0.00049	CcSEcCtD
Fondaparinux sodium—Vomiting—Methotrexate—lymphatic system cancer	0.000471	0.000471	CcSEcCtD
Fondaparinux sodium—Rash—Methotrexate—lymphatic system cancer	0.000467	0.000467	CcSEcCtD
Fondaparinux sodium—Dermatitis—Methotrexate—lymphatic system cancer	0.000467	0.000467	CcSEcCtD
Fondaparinux sodium—Headache—Methotrexate—lymphatic system cancer	0.000464	0.000464	CcSEcCtD
Fondaparinux sodium—Nausea—Methotrexate—lymphatic system cancer	0.00044	0.00044	CcSEcCtD
